Tag: Amplitude Therapeutics
-
Eli Lilly Moves Into Trans-Amplifying RNA Vaccines With Amplitude Deal
Eli Lilly is expanding into next-generation RNA vaccines through a collaboration with Amplitude Therapeutics, gaining access to a trans-amplifying RNA platform designed to separate the replicase from the antigen payload and support multiple infectious-disease vaccine programs.
-
How Trans-Amplifying RNA Could Extend the mRNA Platform
Trans-amplifying RNA separates the replicase machinery from the antigen payload, creating a two-RNA amplification system. This BP Science explainer compares taRNA with conventional mRNA and self-amplifying RNA and examines why the split architecture could make amplified RNA vaccines more modular.